Trials / Active Not Recruiting
Active Not RecruitingNCT06921759
A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Lebrikizumab in Adult and Adolescent Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 206 (estimated)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to assess the efficacy of lebrikizumab versus placebo on skin lesions in adults and adolescent participants with atopic hand and foot dermatitis. This study lasts up to 32 weeks, including a 6-week screening period, a 16-week treatment period, and a safety follow-up visit 12 weeks after the last dose.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lebrikizumab | Administered SC |
| DRUG | Placebo | Administered SC |
Timeline
- Start date
- 2025-04-21
- Primary completion
- 2026-05-01
- Completion
- 2026-07-01
- First posted
- 2025-04-10
- Last updated
- 2026-04-17
Locations
79 sites across 8 countries: United States, Argentina, Australia, Canada, Japan, Mexico, South Korea, Taiwan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06921759. Inclusion in this directory is not an endorsement.